Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphoma.

The letter to the editor discusses the importance of long-term follow-up of autologous stem cell transplantation (ASCT) for mantle cell lymphoma (MCL). A retrospective study in Alberta, Canada, involving 141 patients who underwent ASCT as part of first-line therapy for MCL between 2000 and 2022, revealed a median progression-free survival (PFS) of 11.3 years and an overall survival (OS) of 14.0 years. The study suggests that ASCT achieves durable remissions in MCL, with a subset of patients experiencing remissions lasting 10-20 years, indicating potential functional cure. The findings highlight the need for further research and longer-term follow-up data to determine the efficacy of ASCT in MCL treatment. [Extracted from the article]